AUMED, a.s. has received support for the project “Innovation in the Production of Immunological Preparations”

AUMED has received support for the project “Innovation in the Production of Immunological Preparations,” registration number CZ.01.01.01/02/24_051/0004982.

The essence of the project is the implementation of mass production of a result achieved through the company’s own research and development: a lyophilized tablet of the medicinal product TFI. In previous research projects, the TFI product was fully developed and tested for safety and efficacy in preclinical studies. Additionally, the production and quality control of this preparation was established at the level of an investigational medicinal product. This status was successfully certified by the national regulatory authority (SÚKL), which also granted approval for the initiation of clinical trials of TFI.

The company expects that within two years, both the clinical trials and the registration process will be completed, followed by the launch of mass production of the medicine. The submitted project is aimed at supporting the implementation of mass production and related quality control.

The project will receive financial support from the EU under the Operational Programme Enterprise and Innovation for Competitiveness 2014–2020, INNOVATION Call – Call II